• License and distribution agreement for Bronchitol and Aridol converted from 10-year to indefinite
• BTC to earn royalties from sales in Singapore and Malaysia
• BTC granted first right of refusal to Arna Pharma's new product pipeline

BTC Health (ASX: BTC) has announced that its wholly-owned investee company, BTC Pharma, has amended its existing License and Distribution Agreement for the Bronchitol and Aridol products with Arna Pharma. Under the terms of the amendment, BTC Pharma has assigned Singapore and Malaysia distribution rights to the Products to Arna Pharma. Arna Pharma will pay BTC Pharma a single-digit royalty on sales in these markets for the first 3 years and has granted BTC Pharma an indefinite license to the Products for the Australian and New Zealand markets. Arna Pharma is building a pipeline of novel pharmaceutical products and has granted BTC Pharma the first right of refusal to commercialise its specialty products in the Australian and New Zealand markets. BTC Health Executive Chairman Dr Richard Treagus commented that the expanded partnership agreement combines the strengths of Arna Pharma's product development and manufacturing capabilities with BTC Pharma's distribution and marketing expertise, and they are excited by the potential of bringing novel pharmaceutical products to Australian patients. Arna Pharma Managing Director, Mr Hemant Gulhane, stated that they are delighted to strengthen their partnership with BTC Pharma, extending their collaboration to new markets, and that the agreement reflects their shared commitment to delivering innovative respiratory solutions to patients in Singapore and Malaysia. With an indefinite license for Bronchitol and Aridol, they are positioned for long-term success, and BTC Pharma's first right of refusal for their new product pipeline underscores the trust in Arna Pharma's innovation.